Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

McKesson
Teva
US Department of Justice
QuintilesIMS
Chubb
Colorcon
Novartis
AstraZeneca
Moodys
Harvard Business School

Generated: August 21, 2017

DrugPatentWatch Database Preview

Claims for Patent: ► Subscribe

« Back to Dashboard

Claims for Patent: ► Subscribe

Title: Method of treating anxiety-related disorders using sertraline
Abstract:A method of treating anxiety-related disorders comprising administering to a human in need of such treatment an amount of the compound (1S-cis)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthalenam ine also known by the generic name sertraline, or a pharmaceutically acceptable salt thereof, effective in preventing or alleviating anxiety and the symptoms associated with anxiety-related disorders.
Inventor(s): Doogan; Declan P. (Canterbury, GB2), Scappaticci; Karen A. (New York, NY), Hackett; Elizabeth (New York, NY)
Assignee: Pfizer Inc. (New York, NY)
Application Number:07/431,000
Patent Claims: 1. A method of treating an anxiety-related disorder comprising administering to a patient in need of such treatment an amount of the compound (1S-cis)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthalenam ine, or a pharmaceutically acceptable salt thereof, effective in preventing or alleviating anxiety and the symptoms associated with such disorder.

2. A method according to claim 1 wherein said anxiety-related disorder is selected from the group consisting of panic disorder, generalized anxiety disorder, agoraphobia, simple phobias, social phobia, posttraumatic stress disorder, obsessive-compulsive disorder, and avoidant personality disorder.

3. A method according to claim 1, wberein said anxiety-related disorder is panic disorder.

4. A method according to claim 1, wberein said anxiety-related disorder is generalized anxiety disorder.

5. A method according to claim 1, wherein said anxiety-related disorder is agoraphobia.

6. A method according to claim 1, wherein said anxiety-related disorder is social phobia.

7. A method according to claim 1, wherein said anxiety-related disorder is a simple phobia.

8. A method according to claim 1, wherein said anxiety-related disorder is posttraumatic stress disorder.

9. A method according to claim 1, wherein said anxiety-related disorder is avoidant personality disorder.

10. A method according to claim 1, wherein said anxiety-related disorder is obsessive-compulsive disorder.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Novartis
Accenture
Julphar
Dow
Chinese Patent Office
Moodys
Federal Trade Commission
Harvard Business School
Cipla
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot